| 利妥昔单抗在特发性血小板减少性紫癜中的应用进展 |
| |
| 引用本文： | 张莲兴. 利妥昔单抗在特发性血小板减少性紫癜中的应用进展[J]. 医学综述, 2010, 16(17): 2670-2672 |
| |
| 作者姓名： | 张莲兴 |
| |
| 作者单位： | 新疆医科大学研究生院,乌鲁木齐,830000 |
| |
| 摘 要： | 现已证实特发性血小板减少性紫癜(ITP)是因免疫机制引起血小板破坏增加的临床综合征,又称免疫性血小板减少性紫癜。CD20单克隆抗体利妥昔单抗是一种新型生物应答调节剂,目前被越来越多地应用于包括ITP在内的多种免疫性疾病。现就利妥昔单抗治疗ITP的进展予以综述。
|
| 关 键 词： | 利妥昔单抗 单克隆抗体 特发性血小板减少性紫癜 |
The Application of Rituximab in Idiopathic Thrombocytopenic Purpura |
| |
| ZHANG Lian-xing. The Application of Rituximab in Idiopathic Thrombocytopenic Purpura[J]. Medical Recapitulate, 2010, 16(17): 2670-2672 |
| |
| Authors: | ZHANG Lian-xing |
| |
| Abstract: | It has been confirmed that idiopathic thrombocytopenic purpura(ITP)was a clinical syndrome because platets were much destroied by immunologic mechanism,it is also called immune thrombocytopenic purpura.The anti-CD20 monoclonal antibody rituximab is one of neotype biological response modifiers,it has been used more and more for the treatment of multipal immune disease incluinding idiopathic thrombocytopenic purpura at present.This review article is about rituximab therapy in patients with IPT. |
| |
| Keywords: | Rituximab Monoclonal antibody Idopathic thrombocytopenic urpura |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
